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ORIGINAL ARTICLE
Introduction: The three major clinically relevant mechanisms of 
acquired resistance to epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs) in EGFR mutant lung cancer are a 
second mutation in the EGFR gene (T790M), Met amplification, and 
increased expression of hepatocyte growth factor (HGF). Heat shock 
protein90 (Hsp90) is a 90 kDa molecular chaperone for proteins 
that include EGFR, Met, and echinoderm microtubule-associated 
proetin-like-4-the anaplastic lymphoma kinase. Here, we determined 
whether inhibition of Hsp90 could overcome HGF-triggered EGFR-
TKI resistance in EGFR mutant lung cancer cells.
Methods: The effects of the Hsp90 inhibitor 17-demethoxygeldana-
mycin (17-DMAG) on the growth of lung cancer cells resistant to the 
EGFR-TKI were examined in the presence and absence of HGF, and 
in cells transfected with the HGF gene in vitro and in vivo.
Results: EGFR-TKI erlotinib did not inhibit the growth of HGF-
gene transfected Ma-1 (Ma-1/HGF) cells and H1975 cells, contain-
ing the EGFR L858R and T790M mutations, respectively. Erlotinib 
also did not inhibit the growth of PC-9 and Ma-1 cells, with dele-
tions in EGFR exon19, in the presence of HGF. However, 17-DMAG 
induced apoptosis and markedly inhibited the growth of these cell 
lines, even in the presence of HGF. This inhibition by 17-DMAG 
was associated with decreased expression of EGFR and Met in tumor 
cells. An in vivo model of HGF-triggered erlotinib-resistance, which 
used Ma-1/HGF cells, showed that 17-DMAG markedly suppressed 
tumor growth by decreasing angiogenesis and increasing apoptosis.
Conclusions: Hsp90 inhibitors may overcome HGF-triggered resis-
tance to EGFR-TKIs and may result in more successful treatment of 
patients with EGFR-mutant lung cancers.
Key Words: HGF, EGFR-TKI resistance, Hsp90, Lung cancer, 
EGFR mutation.
(J Thorac Oncol. 2012;7: 1078–1085)
Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) such as exon 19 dele-
tions and exon 21 L858R point mutations are sensitive to 
the EGFR-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib 
and erlotinib.1 Although clinical trials have shown that these 
EGFR-TKIs enhance progression-free survival, compared with 
conventional chemotherapy, in patients with EGFR mutant 
lung cancers,2–5 the vast majority of responders relapse 
after developing resistance to EGFR-TKIs.1,6 Among the clini-
cally relevant mechanisms by which these tumors develop 
resistance to EGFR-TKIs are the T790M secondary mutation 
in EGFR,6,7 Met gene amplification,8 and hepatocyte growth 
factor (HGF) overexpression,9 with HGF overexpression being 
the most frequently detected of the three in our cohort study 
of Japanese patients with acquired resistance to EGFR-TKIs.10 
Moreover, HGF overexpression is frequently accompanied by 
the T790M second mutation10,11 and/or MET gene amplifica-
tion10 in these tumors, indicating that HGF is an important ther-
apeutic target for overcoming tumor resistance to EGFR-TKIs.
Several strategies have been proposed to overcome this 
acquired resistance. For example, new generation EGFR-
TKIs, such as irreversible EGFR-TKIs and TKIs selective for 
mutant EGFR, have been developed to treat T790M associ-
ated resistance.12–14 Combined treatment with an EGFR-TKI 
and a Met-TKI may overcome resistance associated with Met 
amplification.15 Another approach involves the disruption of 
heat shock protein 90 (Hsp90) function, because many mutant 
oncoproteins require Hsp90 for maturation and conformational 
stability and are degraded after Hsp90 inhibition.16 Hsp90 inhib-
itors, including geldanamycin and its derivative 17-demethox-
ygeldanamycin (17-DMAG), have been reported effective in 
overcoming EGFR-TKI resistance caused by T790M second 
mutation and Met amplification.17,18 However, the effect of 
Hsp90 inhibition on HGF-induced resistance to EGFR-TKIs 
is still not known. We therefore evaluated the effect of Hsp90 
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inhibition on HGF-induced resistance to EGFR-TKIs in EGFR-
mutant lung cancer cell lines in vitro and in vivo.
MATERIALS AND METHODS
Cell Cultures and Reagents
The EGFR-mutant human lung adenocarcinoma cell lines 
PC-9 (del E746_A750) and HCC827, with deletions in EGFR 
exon 19, were purchased from Immuno-Biological Laboratories 
Co. (Takasaki, Gunma, Japan) and the American Type Culture 
Collection (Manassas, VA), respectively. Ma-1 cells with an 
EGFR exon 19 deletion, HCC827ER cells with deletions in 
EGFR exon 19 and Met amplification,19 and H1975 cells with the 
L858R/T790M double mutation,20 were kindly provided by Dr. 
E. Shimizu (Tottori University, Tottori, Japan), Dr. T. Mitsudomi 
(Aichi Cancer Center Hospital, Nagoya, Japan), and Dr. Y. 
Sekido (Aichi Cancer Center Research Institute, Nagoya, Japan), 
respectively. Human HGF-gene transfectant (Ma-1/HGF) and 
vector control (Ma-1/Vec) cells were established as described.9 
All of these cell lines were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 10% fetal 
bovine serum (FBS) and antibiotics. All cells were passaged for 
less than 3 months before renewal from frozen, early-passage 
stocks. Cells were regularly screened for mycoplasma, using 
MycoAlert Mycoplasma Detection Kits (Lonza, Rockland, 
ME). Erlotinib, CL-387,785, and 17-DMAG were obtained from 
Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan), Calbiochem 
(San Diego, CA), and Selleck Chemicals (Houston, TX), respec-
tively. Human recombinant HGF was prepared as described.21
HGF Production in Cell Culture Supernatants
Cells (2 × 105) were cultured in 2 ml of RPMI 1640 or 
Dulbecco’s modified eagle medium with 10% FBS for 24 hours, 
washed with phosphate-buffered saline (PBS), and incubated 
for 48 hours in RPMI 1640 with 10% FBS. The culture media 
were harvested and centrifuged, and the supernatants were 
stored at –70°C until analysis. HGF was measured by enzyme-
linked immunosorbent assay (Immunis HGF EIA; B-Bridge 
International, Mountain View, CA; limit of detection, 0.1 ng/ml) 
according to the manufacturer’s instructions. All samples were 
assayed in triplicate. Color intensity was measured at 450 nm 
with a spectrophotometric plate reader. Growth factor concen-
trations were determined by comparison with standard curves.
Cell Growth Assay
Cell proliferation was measured by the 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyl tetrazolium (MTT) dye reduction meth-
od.22 Tumor cells, plated at 2 × 103/100 µl RPMI 1640 plus 10% 
FBS per well in 96-well plates, were incubated for 24 hours; erlo-
tinib, CL-387,785, 17-DMAG, and/or HGF were added to each 
well, and incubation was continued for an additional 72 hours. 
Cell growth was measured with MTT solution (2 mg/ml; Sigma, 
St. Louis, MO), as described.9 Each experiment was performed at 
least three times, each with triplicate samples.
Antibodies and Western Blotting
Protein aliquots of 25 µg each were resolved by sodium 
dodecyl sulfate polyacrylamide gel (Bio-Rad, Hercules, CA) 
electrophoresis and transferred to polyvinylidene difluo-
ride membranes (Bio-Rad). After washing four times, the 
membranes were incubated with Blocking One (Nacalai 
Tesque, Inc., Kyoto, Japan) for 1 hour at room tempera-
ture and overnight at 4°C with primary antibodies to β-actin 
(13E5), MET (25H2), phospho-Met (anti-p-Met, Y1234/
Y1235; 3D7), p-EGFR (Y1068), Akt or p-Akt (S473) (Cell 
Signaling Technology, Beverly, MA), human EGFR (1 µg/ml), 
human/mouse/rat ERK1/ERK2 (0.2 µg/ml), and p-ERK1/
ERK2 (T202/Y204; 0.1 µg/ml) (R&D Systems, Minneapolis, 
MN). After three washes, the membranes were incubated for 
1 hour at room temperature with species-specific horseradish- 
peroxidase–conjugated secondary antibodies. Immunoreactive 
bands were visualized with SuperSignal West Dura Extended 
Duration Substrate (Pierce Biotechnology, Rockford, IL), an 
enhanced chemiluminescent substrate. Each experiment was 
performed at least three times independently.
Cell Apoptosis Assay
Cell apoptosis induced by erlotinib and 17-DMAG 
was measured with an Annexin V-fluorescein isothiocyanate 
Apoptosis Detection Kit I (BD Biosciences, San Jose, CA) 
in accordance with the manufacturer’s directions.9 Cells were 
analyzed on a FACSCalibur flow cytometer with CellQuest 
Software (Becton Dickinson, Franklin Lakes, NJ).
Xenograft Studies in Severe Combined 
Immunodeficiency Mice
Suspensions of Ma-1/Vec and Ma-1/HGF cells (5 × 106) 
were injected subcutaneously into the backs of 5-week-old 
female severe combined immunodeficiency mice (Clea, 
Tokyo, Japan). After 7 days, the mice were randomized to 
(1) no treatment (control group), (2) oral erlotinib (20 mg/kg/
day), (3) intraperitoneal 17-DMAG (10 mg/kg/day in water), 
or (4) oral erlotinib plus intraperitoneal 17-DMAG. Tumor 
size was measured twice per week, and tumor volume was cal-
culated, in mm3, as width2 × length/2. All animal experiments 
complied with the guidelines for the Institute for Experimental 
Animals, Advanced Science Research Center, Kanazawa 
University, Kanazawa, Japan (approval no. AP-081088).
Histological Analyses
Apoptotic cells were detected by terminal deoxynu-
cleotidyl transferase (TUNEL)–mediated nick end labeling 
staining, using the DeadEnd Fluorometric TUNEL system 
(Promega, Madison, WI). Briefly, formalin-fixed, paraffin- 
embedded sections (4 µm thick) were deparaffinized and 
tissues were permeabilized with protease K solution. The 
samples were equilibrated, and DNA strand breaks were 
labeled with fluorescein-12-2-deoxy-uridine-5-triphosphate 
by adding a nucleotide mixture and TUNEL. The reaction 
was stopped by the addition of saline sodium citrate, and the 
localized green fluorescence of apoptotic cells was detected 
by fluorescence microscopy (×400). Proliferating cells were 
detected by incubating tissue sections with Ki-67 antibody 
(Clone MIB-1; DAKO Corp., Glostrup, Denmark). Antigen 
was retrieved by microwaving tissue sections in 10 mM citrate 
buffer (pH 6.0). After incubation with secondary antibody and 
treatment with the Vectastain ABC Kit (Vector Laboratories, 
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Burlingame, CA), peroxidase activity was visualized using the 
diamino benzidine (DAB) reaction. To analyze microvessel 
density, frozen sections (5-µm thick) of xenograft tumors were 
fixed with cold acetone and washed with PBS. After blocking 
endogenous peroxidase activity with 3% aqueous H
2
O
2
 solu-
tion for 10 minutes, the sections were incubated with 5% nor-
mal horse serum, washed, and incubated overnight at 4°C with 
antimouse-CD31 (clone MEC13.3, BD Bioscience) antibody. 
After washing with PBS, the sections were incubated with per-
oxidase conjugated antirat IgG (Cell Signaling Technology) for 
40 minutes. Peroxidase activity was visualized with DAB reac-
tions. The sections were counterstained with hematoxylin.
EGFR was assessed immunohistochemically, using the 
EGFR pharmDx kit (DAKO), as recommended by the manufac-
turer. To detect Met protein, formalin-fixed paraffin-embedded 
tissue sections were incubated with a 1:100 dilution of polyclonal 
rabbit anti-MET antibody overnight at 4°C after microwave anti-
gen retrieval in 0.01 M citrate buffer (pH 6.0). After incubation 
with secondary antibody and treatment with the Vectastain ABC 
Kit), peroxidase activity was visualized using DAB reactions.
Quantification of Immunohistochemistry and 
Immunofluorescence
The five areas containing the highest numbers of stained 
cells within a section were selected for histologic quantitation 
by light or fluorescent microscopy at 400-fold magnification. 
All results were independently evaluated by two investigators 
(H.K. and T.N.).
Statistical Analysis
Between-group comparisons were assessed by two-
tailed Student’s t tests. All analyses were performed using 
GraphPad Software (GraphPad Software, Inc., La Jolla, CA). 
A p value < 0.001 was considered statistically significant.23
RESULTS
17-DMAG Inhibits Growth of EGFR-Mutant 
Lung Cancer Cells in the Presence of HGF
PC-9, HCC827, and Ma-1 are human lung adenocarci-
noma cell lines with deletions of exon 19 of EGFR, resulting in 
constitutive activation of this gene. These three cell lines were 
sensitive to erlotinib, whereas HGF induced erlotinib resistance 
(Fig. 1A, B, D). The Hsp90 inhibitor 17-DMAG alone mark-
edly inhibited the growth of these three cells lines, with an IC
50
 
(half maximal inhibitory concentration) lower than that of erlo-
tinib in PC-9 (0.01 µmol/l versus 0.03 µmol/l) and Ma-1 (0.01 
µmol/l versus 0.03 µmol/l) cells and a similar IC
50
 in HCC827 
(0.01 µmol/l) cells. Under these experimental conditions, HGF did 
FIGURE 1.  17-DMAG suppresses the in vitro growth of EGFR mutant lung cancer cells in the presence of HGF. Tumor cells 
were continuously treated with increasing concentrations of EGFR-TKI, erlotinib (PC-9, HCC827, Ma-1, Ma-1/Vec, and Ma-1/
HGF), CL-387,785 (H1975), or 17-DMAG, with or without HGF (20 ng/ml), and cell growth was determined after 72 hours by 
MTT assay. Data shown are representative of five independent experiments. Error bars indicate SD of triplicate cultures.  
EGFR, epidermal growth factor receptor; HGF, hepatocyte growth factor; TKI, tyrosine kinase inhibitor.
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not decrease the sensitivity of the three cell lines to 17-DMAG. 
In parallel experiments, we used H1975, a human lung adenocar-
cinoma cell line with both an exon 20 T790M gatekeeper muta-
tion and an exon 21 L858R mutation in EGFR. Although these 
cells were resistant to erlotinib (data not shown), they were sen-
sitive to an irreversible EGFR-TKI CL-387,785,24 as described 
(Fig. 1C). We found that 17-DMAG alone inhibited the growth 
of H1975 cells, with an IC
50
 much lower than that of CL-387,785 
(0.03 µmol/l versus 0.5 µmol/l); and also inhibited the growth of 
HCC827ER cells, with a deletion of exon 19 of EGFR and Met 
gene amplification, with an IC
50 
of 0.03 µmol/l (Supplemental 
Figure 1, Supplemental Digital Content, http://links.lww.com/
JTO/A267). HGF did not decrease the sensitivity of H1975 and 
HCC827ER cells to 17-DMAG. Incubation of PC-9, H1975, and 
HCC827ER cells, harboring mutant EGFR, with the combination 
of 17-DMAG plus EGFR-TKI showed that 17-DMAG did not sen-
sitize these cells to EGFR-TKI treatment in vitro (Supplemental 
Figures 1 and 2, Supplemental Digital Content, http://links.
lww.com/JTO/A267). Taken to-gether, these results suggest that 
17-DMAG may overcome HGF-induced resistance to reversible 
and irreversible EGFR TKIs in lung cancer cells containing an 
EGFR activating and gatekeeper mutation, respectively.
Our previous study demonstrated that, in patients with 
non–small-cell lung cancer, HGF is detected primarily in cancer 
cells with acquired resistance to EGFR-TKIs, suggesting that the 
production of HGF by these cells occurs via an autocrine mecha-
nism. To further explore the effect of 17-DMAG on autocrine 
HGF, we generated stable HGF-gene transfectants in Ma-1 cells 
(Ma-1/HGF); as a control, we generated Ma-1/Vec cells trans-
fected with vector alone. Ma-1/HGF cells secreted high concen-
trations of HGF (27.8 ± 0.9 ng/ml), whereas the concentrations of 
HGF secreted by Ma-1 and Ma-1/Vec cells were under the limit of 
detection (Supplemental Figure 3, Supplemental Digital Content, 
http://links.lww.com/JTO/A267). In addition, Ma-1/HGF cells 
became resistant to erlotinib. We found that 17-DMAG inhibited 
the growth of both Ma-1/Vec and Ma-1/HGF cells, with IC
50
s of 
0.01 µmol/l for both (Fig. 1E and 1F), whereas the combination 
of 17-DMAG plus erlotinib did not inhibit the growth of Ma-1/
HGF cells, indicating that 17-DMAG did not sensitize these 
cells to erlotinib in vitro (Supplemental Figure 2, Supplemental 
Digital Content, http://links.lww.com/JTO/A267). These find-
ings indicated that 17-DMAG circumvented resistance to HGF 
via both autocrine and paracrine mechanisms.
17-DMAG Reduces Met Protein Expression and 
Inhibits Downstream Pathways Even in the 
Presence of HGF
To explore the molecular mechanism by which 
17-DMAG inhibited cell growth, even in the presence of 
HGF, we examined the protein expression and phospho-
rylation status of Met, EGFR, and their downstream mol-
ecules (PI3K/Akt and ERK1/2) in PC-9 and Ma-1 cells by 
Western blotting (Fig. 2). PC-9 and Ma-1 cells expressed 
FIGURE 2.  17-DMAG suppresses EGF and Met protein expression and phosphorylation even in the presence of HGF. PC-9, 
Ma-1, Ma-1/Vec, and Ma-1/HGF tumor cells were treated with or without erlotinib (0.3 μmol/l) or 17-DMAG (0.3 μmol/l) for 
24 hours, and then stimulated with or without HGF (20 ng/ml) for 10 minutes. The resultant cells were lysed, and the indicated 
proteins were detected by immunoblotting. EGF, epidermal growth factor; HGF, hepatocyte growth factor.
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EGFR and Met proteins, both of which were phosphorylated, 
as were the downstream molecules Akt and ERK1/2. Although 
HGF alone did not affect the phosphorylation of EGFR, it 
stimulated the phosphorylation of Met, thereby activating Akt 
and ERK1/2. In the absence of HGF, erlotinib inhibited the 
phosphorylation of EGFR, but not of Met, thereby inhibiting 
the phosphorylation of Akt and ERK1/2. In the absence of 
HGF, erlotinib inhibited the phosphorylation of EGFR, but 
not of Met, thereby inhibiting the phosphorylation of Akt and 
ERK1/2. In the presence of HGF, erlotinib failed to inhibit the 
phosphorylation of Met, Akt, and ERK1/2, although it inhibited 
EGFR phosphorylation.9 17-DMAG decreased the expression 
of EGFR and Met proteins and inhibited their phosphorylation 
and the phosphorylation of Akt and ERK1/2, irrespective of 
the presence of HGF. Similar results were observed in Ma-1/
HGF cells. These results suggested that 17-DMAG overcomes 
resistance to HGF, predominantly by inhibiting the expression 
of EGFR and Met proteins, and then inhibits the expression of 
the downstream proteins Akt and ERK1/2.
17-DMAG Induces Apoptosis of EGFR-Mutant 
Lung Cancer Cells Even in the Presence of HGF
Flow-cytometry analyses with Annexin V further con-
firmed that erlotinib induced apoptosis of Ma-1/Vec cells in the 
absence, but not the presence, of HGF (Supplemental Figure 
4, Supplemental Digital Content, http://links.lww.com/JTO/
A267). In contrast, 17-DMAG induced apoptosis in both the 
presence and absence of HGF. Moreover, 17-DMAG, but not 
erlotinib, induced apoptosis of Ma-1/HGF cells. These find-
ings indicated that 17-DMAG induces apoptosis and reduces 
cell growth even in the presence of HGF.
17-DMAG Overcomes HGF-Induced Erlotinib 
Resistance In Vivo
We next evaluated whether 17-DMAG could overcome 
HGF-induced resistance to erlotinib in vivo. Oral adminis-
tration of erlotinib and/or 17-DMAG markedly inhibited the 
growth of Ma-1/Vec-tumors (Fig. 3A and 3C). In contrast, 
FIGURE 3.  17-DMAG overcomes HGF-induced erlotinib resistance in vivo. Ma-1/Vec (A) or Ma-1/HGF (B) cells (5 × 106 each)  
were inoculated subcutaneously into SCID mice on day 0. Mice received oral erlotinib (20 mg/kg/day) or intraperitoneal 17-DMAG 
(10 mg/kg/day), starting on day 7. Tumor size was measured twice a week and tumor volumes were calculated as described in 
Materials and Methods. Error bars indicate SEs of six tumors. C, Macroscopic appearances of representative tumors harvested on  
day 21. *p < 0.01 compared with the control group (Student’s t test). 17-DMAG, 17-Dimethylaminoethylamino-17-
demethoxygeldanamycin; HGF, hepatocyte growth factor; SCID, severe combined immunodeficiency.
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FIGURE 4.  17-DMAG inhibits EGFR and Met expression in vivo. Ma-1/Vec or Ma-1/HGF cells (5 × 106 each) were inoculated 
subcutaneously into SCID mice on day 0. Mice received oral erlotinib (20 mg/kg/day) or intraperitoneal 17-DMAG (10 mg/kg/
day), starting on day 7. Two hours after treatment on day 11, the mice were sacrificed, and their tumors were harvested and 
examined histologically. Sections were stained with DAPI (nuclear stain), TUNEL (FITC), EGFR (IHC), and Met (IHC), respectively. 
Bars indicate 50 μm. 17-DMAG, 17-demethoxygeldanamycin; EGF, epidermal growth factor; HGF, hepatocyte growth factor; 
SCID, severe combined immunodeficiency; DAPI, 4’,6-diamidino-2-phenylindole; TUNEL, terminal deoxynucleotidyl transferase; 
FITC, fluorescein isothiocyanate; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry.
erlotinib failed to inhibit the growth of Ma-1/HGF-tumors, 
indicating that HGF induced resistance to erlotinib in vivo. 
Under these experimental conditions, 17-DMAG markedly 
suppressed the growth of Ma-1/HGF tumors, whereas the 
combination of 17-DMAG plus erlotinib did not sensitize 
to erlotinib (Supplemental Figure 5, Supplemental Digital 
Content, http://links.lww.com/JTO/A267). These results indi-
cated that 17-DMAG may overcome HGF-induced resistance 
to EGFR-TKIs in vivo (Fig. 3B and 3C).
17-DMAG Inhibits EGFR and Met Expression 
and Angiogenesis In Vivo
We finally assessed angiogenesis and expression of 
EGFR and Met proteins in Ma-1/HGF-tumors treated with or 
without erlotinib or 17-DMAG. Control tumor cells expressed 
both EGFR and Met. Although treatment with erlotinib did 
not affect their expression of EGFR or Met, treatment with 
17-DMAG inhibited their expression of EGFR and Met, indi-
cating the mode of action of 17-DMAG. Moreover, treatment 
with 17-DMAG, but not erlotinib, increased the number of 
apoptotic cells. However, the numbers of proliferating control, 
erlotinib-treated, and 17-DMAG-treated cells were similar 
(Fig. 4, Fig. 5A and 5B, Supplemental Figure 6, Supplemental 
Digital Content, http://links.lww.com/JTO/A267). Moreover, 
17-DMAG treatment inhibited the angiogenesis of Ma-1/
HGF tumors (Fig. 5C, Supplemental Figure 7, Supplemental 
Digital Content, http://links.lww.com/JTO/A267). These 
results suggested that 17-DMAG treatment inhibited tumor 
growth by inducing tumor-cell apoptosis, presumably by 
affecting the expression of EGFR and Met and by decreasing 
angiogenesis.
DISCUSSION
We have shown here that inhibition of Hsp90 by 17-DMAG 
could reduce the levels of EGFR and Met proteins and angiogen-
esis even in the presence of HGF, thus inhibiting the growth of 
EGFR-mutant lung cancer cells in vitro and in vivo. These find-
ings suggest that HGF-induced EGFR-TKI-resistance in EGFR-
mutant lung cancer could be overcome by Hsp90 inhibition.
Hsp90 is involved in stabilizing various oncogene prod-
ucts, including mutant EGFR and echinoderm microtubule-
associated proetin-like-4-the anaplastic lymphoma kinase 
(EML4-ALK) fusion protein.25,26 Hsp90 stabilizes various 
types of mutant EGFR, including proteins with exon 19 dele-
tions and the T790M and L858R mutations,17 and amplified 
Met.18 We found that Hsp90 is also involved in the expres-
sion of Met stimulated by HGF, suggesting that inhibition of 
Hsp90 may overcome all three major mechanisms of resis-
tance to EGFR-TKIs in EGFR-mutant lung cancers, includ-
ing the T790M gatekeeper mutation, Met amplification, and 
increased expression of HGF. Furthermore, Hsp90 inhibitors 
are likely effective in EML4-ALK lung cancers,27–29 overcom-
ing acquired resistance to ALK inhibitors caused by ALK 
gene amplification and the L1196M gatekeeper mutation in 
ALK.29 Thus, Hsp90 may be an ideal target in patients with 
lung cancers containing oncogene alterations, such as EGFR 
1084 Copyright © 2012 by the International Association for the Study of Lung Cancer
Koizumi et al. Journal of Thoracic Oncology  •  Volume 7, Number 7, July 2012
mutations and EML4-ALK gene translocations, before and 
after acquiring resistance to kinase inhibitors such as gefi-
tinib, erlotinib, and crizotinib. Conversely, the efficacy of 
17-DMAG was restricted not only to the erlotinib resistance, 
but also to EGFR wild-type cell lines independent of HGF 
treatment (data not shown), indicating that Hsp90 inhibitor is 
a general modifier of antitumor activity in combination with 
other anticancer drugs, and the agent could be used for over-
coming the resistance. These findings also indicated that the 
combination of trastuzumab and Hsp90 inhibitor has antitu-
mor activity in patients with trastuzumab-refractory HER-2 
overexpressing breast cancer.30
Clarification of molecular mechanisms is essential 
for developing treatment strategies. To overcome resistance 
caused by HGF-triggered activation of the Met/PI3K/Akt 
pathway, it is necessary to simultaneously block two signaling 
pathways, those associated with mutant EGFR and HGF-Met. 
The HGF-Met pathway may be inhibited by several mecha-
nisms, including HGF neutralization, Met kinase inhibition, 
and inhibition of downstream molecules.31 The EGFR and 
HGF-Met pathways can be inhibited by two compounds. For 
example, an anti-HGF neutralizing antibody and an HGF 
antagonist (NK4), when combined with EGFR-TKIs, dra-
matically reversed HGF-induced resistance in vitro and in 
vivo.32 Moreover, transient but intensive inhibition of PI3K/
Akt by PI3K inhibitors and gefitinib successfully overcame 
HGF-induced EGFR-TKI resistance in vitro and in vivo.33 
The feasibility of these strategies, however, should be evalu-
ated carefully in clinical trials. Hsp90 inhibition may have 
an advantage, however, because inhibition by a single agent 
may be sufficient. Recently reported results of early-phase 
clinical trials have shown the feasibility of several Hsp90 
inhibitors.28,34,35
HGF is a mediator that regulates multiple biological 
functions, including cell motility and invasion.36 Moreover, 
HGF plays an important role in angiogenesis by cooperat-
ing with vascular endothelial growth factor .37 We previously 
reported that HGF stimulated vascular endothelial growth 
factor production by EGFR-mutant lung cancer cells, thereby 
facilitating angiogenesis and tumor growth in xenograft mod-
els. Tumors produced by HGF-gene transfected (Ma-1/HGF) 
cells were more vascularized and grew faster than those pro-
duced by control (Ma-1/Vec) cells. Moreover, 17-DMAG 
treatment inhibited the angiogenesis of Ma-1/HGF, but not 
Ma-1/Vec tumors, suggesting that 17-DMAG may overcome 
HGF-induced angiogenesis. Thus, HGF inhibition would sup-
press angiogenesis, thereby inhibiting tumor progression. 
Therefore, in HGF-triggered, EGFR-TKI-resistant lung can-
cers, Hsp90 inhibitors may control tumor growth not only by 
decreasing client proteins, EGFR and Met, but also by inhibit-
ing HGF-induced angiogenesis.
Our findings, however, indicate that Hsp90 inhibitors 
have limitations. Although our in vivo experiments showed 
that 17-DMAG reduced tumor growth significantly, it failed 
to shrink tumors produced by Ma-1/Vec and Ma-1/HGF cells. 
These results are in agreement with previous findings, show-
ing that treatment with the Hsp90 inhibitor, IPI-504, markedly 
suppressed the growth of H3122 tumor cells containing the 
EML4-ALK fusion gene, but that these tumors regrew dur-
ing treatment.26 Further experiments are warranted to clarify 
this mechanism; such experiments are now ongoing in our 
laboratory.
In conclusion, we demonstrated that Hsp90 inhibition 
may overcome HGF-triggered resistance to EGFR-TKIs in 
EGFR-mutant lung cancer. Several early-phase clinical trials 
have shown the efficacy and feasibility of Hsp90 inhibitors in 
lung cancer patients. Further clinical development of Hsp90 
inhibitors is warranted for EGFR-mutant lung cancer patients 
who become refractory to EGFR-TKIs.
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